Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours Β· Estimated delivery Aug 20 - Aug 25
New molecular forms of cholecystokinin
The results showed that in high risk patients with T2D liraglutide reduced the risk of MACE by 13% (primary endpoint included cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke) ( In the ELIXA and the EXSCEL trials, GLP-1RAs (once daily lixisenatide and once weekly exenatide, respectively) didnt provide benefit in MACE reduction compared to placebo, but were non-inferior to placebo for the primary composite outcome of MACE
Peptide deep dive
1 In a study of 3,297 patients with established cardiovascular disease already on standard treatment, the addition of semaglutide reduced the composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 2.3 percentage points as compared with placebo (6.6% vs
